Trial Profile
Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Chronic heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms SilHF
- 12 May 2022 Status changed from active, no longer recruiting to completed, according to Results published in the European Journal of Heart Failure.
- 12 May 2022 Results assessing safety, tolerability, and efficacy of sildenafil in patients with HFrEF and indirect evidence of PHT, published in the European Journal of Heart Failure.
- 04 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.